Related Experiment Video
Updated: May 29, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Continuous treatment in multiple myeloma - ready for prime time?
1Medizinische Klinik und Poliklinik II, Schwerpunkt Hämatologie und Onkologie, Universitätsklinikum Würzburg, Germany.
Onkologie
|September 22, 2011
Summary
Continuous lenalidomide therapy significantly improves event-free survival in multiple myeloma patients. While effective, its impact on overall survival requires further investigation.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Non-genotoxic drugs show promise in hematologic malignancies.
- Alkylating chemotherapy remains standard for 'medically fit' multiple myeloma patients.
- Immunomodulatory drugs like thalidomide and lenalidomide represent a novel therapeutic class.
Purpose of the Study:
- To evaluate the efficacy of continuous lenalidomide therapy in multiple myeloma.
- To compare continuous lenalidomide with placebo in clinical trials.
- To assess the safety and tolerability of lenalidomide compared to thalidomide.
Main Methods:
- Analysis of preliminary clinical trial data.
- Comparison of event-free survival between lenalidomide and placebo groups.
- Assessment of side effect profiles for thalidomide and lenalidomide.
Main Results:
- Continuous lenalidomide therapy demonstrated highly significant improvements in event-free survival.
- Lenalidomide exhibits a more favorable side effect profile than thalidomide, allowing for continuous administration.
- Ongoing trials explore lenalidomide maintenance post-conventional therapy and stem cell transplantation.
Conclusions:
- Continuous lenalidomide therapy is a promising strategy for multiple myeloma, significantly improving event-free survival.
- Lenalidomide's improved tolerability supports its use as a continuous treatment option.
- Further follow-up is needed to determine if improved event-free survival translates to an overall survival benefit.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...